Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Edesa Biotech Inc

EDSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$5.35

▼ -1.47%

Market Cap $51.58M · Vol 9.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$51.58M

Micro Cap

Div Yield

N/A

EPS Growth

-47.51%

YoY

RSI (14)

50.00

Momentum

Beta

1.08

vs Market

52W High

$20.20

73.51% below

52W Low

$0.72

643.06% above

Volume

9.92K

Avg 12.72K

P/B

5.53

Price-to-book

ROE

N/A

Return on equity

Free Float

75.40%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Edesa Biotech Inc (EDSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EDSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.52%

-20.62%

-63.38%

+424.51%

YTD

+268.97%

+136.73%

-11.18%

-83.35%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-7,185,520.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-82.85% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.53
P/FCF	N/A
EPS Growth	-47.51%
Outstanding Shares	9.64M

Technical Indicators

50-Day SMA	$6.24
200-Day SMA	$5.05
RSI (14)	50.00
Beta	1.08
52-Week High	$20.20
52-Week Low	$0.72

Volume Today	9.92K
Avg Daily Volume (30D)	12.72K
Relative Volume	0.78x
Volatility (10D)	49.52
Volatility (30D)	64.97
Free Float	75.40%

Analyst Consensus

BUY

Current Price $5.35

Mean Target $15.00

52W Low$0.72 52W High$20.20

Current

Target

$0.72 $20.20

Current Analyst target

+180.37% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SPM284

ISINCA27966L3065

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.